Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.

Schumich A, Maurer-Granofszky M, Attarbaschi A, Pötschger U, Buldini B, Gaipa G, Karawajew L, Printz D, Ratei R, Conter V, Schrappe M, Mann G, Basso G, Dworzak MN; AIEOP-BFM-ALL-FLOW-Study Group.

Pediatr Blood Cancer. 2018 Dec 18:e27590. doi: 10.1002/pbc.27590. [Epub ahead of print]

PMID:
30561169
2.

Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial.

Biondi A, Gandemer V, De Lorenzo P, Cario G, Campbell M, Castor A, Pieters R, Baruchel A, Vora A, Leoni V, Stary J, Escherich G, Li CK, Cazzaniga G, Cavé H, Bradtke J, Conter V, Saha V, Schrappe M, Grazia Valsecchi M.

Lancet Haematol. 2018 Dec;5(12):e641-e652. doi: 10.1016/S2352-3026(18)30173-X.

PMID:
30501871
3.

Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP).

Parasole R, Valsecchi MG, Silvestri D, Locatelli F, Barisone E, Petruzziello F, Putti MC, Micalizzi C, Colombini A, Mura R, Mina T, Testi AM, Notarangelo LD, Santoro N, Casini T, Consarino C, Nigro LL, Ziino O, Giagnuolo G, Rizzari C, Conter V.

Blood Cancer J. 2018 Nov 15;8(12):115. doi: 10.1038/s41408-018-0150-z. No abstract available.

4.

Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor.

Biondi A, Cario G, De Lorenzo P, Castor A, Conter V, Leoni V, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Attarbaschi A, Li CK, Vora A, Bradtke J, Saha V, Valsecchi MG, Schrappe M.

Haematologica. 2019 Jan;104(1):e13-e16. doi: 10.3324/haematol.2018.199422. Epub 2018 Sep 13. No abstract available.

5.

Genetic risk factors for VIPN in childhood acute lymphoblastic leukemia patients identified using whole-exome sequencing.

Abaji R, Ceppi F, Patel S, Gagné V, Xu CJ, Spinella JF, Colombini A, Parasole R, Buldini B, Basso G, Conter V, Cazzaniga G, Leclerc JM, Laverdière C, Sinnett D, Krajinovic M.

Pharmacogenomics. 2018 Oct;19(15):1181-1193. doi: 10.2217/pgs-2018-0093. Epub 2018 Sep 7.

PMID:
30191766
6.

Oral Nutritional Supplementation in Children Treated for Cancer in Low- and Middle-Income Countries Is Feasible and Effective: the Experience of the Children's Hospital Manuel De Jesus Rivera "La Mascota" in Nicaragua.

Peccatori N, Ortiz R, Rossi E, Calderon P, Conter V, García Y, Biondi A, Espinoza D, Ceppi F, Mendieta L, Melzi ML.

Mediterr J Hematol Infect Dis. 2018 Jun 23;10(1):e2018038. doi: 10.4084/MJHID.2018.038. eCollection 2018.

7.

The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols.

Paganin M, Grillo MF, Silvestri D, Scapinello G, Buldini B, Cazzaniga G, Biondi A, Valsecchi MG, Conter V, Te Kronnie G, Basso G.

Br J Haematol. 2018 Sep;182(5):705-711. doi: 10.1111/bjh.15449. Epub 2018 Jun 25.

PMID:
29938780
8.

Long-term results of the AIEOP MH'96 childhood Hodgkin's lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy.

Burnelli R, Rinieri S, Rondelli R, Todesco A, Bianchi M, Garaventa A, Zecca M, Indolfi P, Conter V, Santoro N, Aricò M, Cesaro S, D'amico S, Farruggia P, De Santis R, Locatelli F, Pileri SA, Scarzello G, Mascarin M, Vecchi V; AIEOP (Italian Association of Pediatric Hematology and Oncology) and Pediatric Hodgkin’s Lymphoma working Group.

Leuk Lymphoma. 2018 Nov;59(11):2612-2621. doi: 10.1080/10428194.2018.1435872. Epub 2018 Feb 16.

PMID:
29448858
9.

Initial Results of Peripheral-Blood Stem-Cell Mobilization, Collection, Cryopreservation, and Engraftment After Autologous Transplantation Confirm That the Capacity-Building Approach Offers Good Chances of Success in Critical Contexts: A Kurdish-Italian Cooperative Project at the Hiwa Cancer Hospital, Sulaymaniyah.

Majolino I, Mohammed D, Hassan D, Ipsevich F, Abdullah C, Mohammed R, Palmas A, Possenti M, Noori D, Ali D, Karem H, Salih S, Vacca M, Del Fante C, Ostuni A, Frigato A, Massei MS, Manna A, Vasta S, Gabriel M, Verna M, Rovelli A, Conter V, Ali K, Othman D.

J Glob Oncol. 2018 Sep;(4):1-8. doi: 10.1200/JGO.17.00101. Epub 2017 Dec 15.

10.

DNA variants in DHFR gene and response to treatment in children with childhood B ALL: revisited in AIEOP-BFM protocol.

Ceppi F, Gagné V, Douyon L, Quintin CJ, Colombini A, Parasole R, Buldini B, Basso G, Conter V, Cazzaniga G, Krajinovic M.

Pharmacogenomics. 2018 Jan;19(2):105-112. doi: 10.2217/pgs-2017-0153. Epub 2017 Dec 6.

PMID:
29210328
11.

Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).

Schrappe M, Bleckmann K, Zimmermann M, Biondi A, Möricke A, Locatelli F, Cario G, Rizzari C, Attarbaschi A, Valsecchi MG, Bartram CR, Barisone E, Niggli F, Niemeyer C, Testi AM, Mann G, Ziino O, Schäfer B, Panzer-Grümayer R, Beier R, Parasole R, Göhring G, Ludwig WD, Casale F, Schlegel PG, Basso G, Conter V.

J Clin Oncol. 2018 Jan 20;36(3):244-253. doi: 10.1200/JCO.2017.74.4946. Epub 2017 Nov 17.

12.

Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.

Cazzaniga G, De Lorenzo P, Alten J, Röttgers S, Hancock J, Saha V, Castor A, Madsen HO, Gandemer V, Cavé H, Leoni V, Köhler R, Ferrari GM, Bleckmann K, Pieters R, van der Velden V, Stary J, Zuna J, Escherich G, Stadt UZ, Aricò M, Conter V, Schrappe M, Valsecchi MG, Biondi A.

Haematologica. 2018 Jan;103(1):107-115. doi: 10.3324/haematol.2017.176917. Epub 2017 Oct 27.

13.

Primary mediastinal large B-cell lymphoma: Outcome of a series of pediatric patients treated with high-dose methotrexate and cytarabine plus anti-CD20.

Pillon M, Carraro E, Mussolin L, Conter V, Tondo A, Aricò M, Mura R, Sala A, Vinti L, Buffardi S, Pierani P, d'Amore ESG, Basso G.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26855. Epub 2017 Oct 19.

PMID:
29049862
14.

Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL.

Locatelli F, Valsecchi MG, Möricke A, Zimmermann M, Gruhn B, Biondi A, Kulozik AE, Silvestri D, Bodmer N, Putti MC, Burdach S, Micalizzi C, Teigler-Schlegel A, Ritter J, Pession A, Cario G, Bielack S, Basso G, Klingebiel T, Vinti L, Rizzari C, Attarbaschi A, Santoro N, Parasole R, Mann G, Karawajew L, Haas OA, Conter V, Schrappe M.

Blood. 2017 Nov 9;130(19):2146-2149. doi: 10.1182/blood-2017-05-782086. Epub 2017 Sep 22. No abstract available.

15.

The capacity-building approach was successful in the start-up process of the first HSCT center in Iraqi Kurdistan.

Majolino I, Rovelli A, Vacca M, Verna M, Canesi M, Conter V, Othman D.

Bone Marrow Transplant. 2017 Dec;52(12):1684-1685. doi: 10.1038/bmt.2017.202. Epub 2017 Sep 18. No abstract available.

PMID:
28920947
16.

Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.

Hinze L, Möricke A, Zimmermann M, Junk S, Cario G, Dagdan E, Kratz CP, Conter V, Schrappe M, Stanulla M.

Leukemia. 2017 Aug;31(8):1840-1842. doi: 10.1038/leu.2017.154. Epub 2017 May 22. No abstract available.

PMID:
28529312
17.

Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations.

Ballerini A, Moro F, Nerini IF, Marzo CM, Di Clemente A, Ferrari M, D'Incalci M, Biondi A, Colombini A, Conter V, Porcu L, Cervo L, Rizzari C, Zucchetti M.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1267-1271. doi: 10.1007/s00280-017-3307-8. Epub 2017 Apr 19.

PMID:
28424964
18.

Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL.

Serafin V, Lissandron V, Buldini B, Bresolin S, Paganin M, Grillo F, Andriano N, Palmi C, Cazzaniga G, Marmiroli S, Conter V, Basso G, Accordi B.

Leukemia. 2017 Apr;31(4):1007-1011. doi: 10.1038/leu.2017.13. Epub 2017 Jan 13. No abstract available.

PMID:
28082737
19.

Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B-Cell Lymphoma treated with the AIEOP LNH-97 protocol.

Pillon M, Mussolin L, Carraro E, Conter V, Aricò M, Vinti L, Garaventa A, Piglione M, Buffardi S, Sala A, Santoro N, Lo Nigro L, Mura R, Tondo A, Casale F, Farruggia P, Pierani P, Cesaro S, d'Amore ES, Basso G.

Br J Haematol. 2016 Nov;175(3):467-475. doi: 10.1111/bjh.14240. Epub 2016 Jul 8.

PMID:
27392319
20.

The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results.

Antillón FG, Blanco JG, Valverde PD, Castellanos M, Garrido CP, Girón V, Letona TR, Osorio EJ, Borrayo DA, Mack RA, Melgar MA, Lorenzana R, Ribeiro RC, Metzger M, Conter V, Rossi E, Valsecchi MG.

Cancer. 2017 Feb 1;123(3):436-448. doi: 10.1002/cncr.30257. Epub 2016 Sep 28.

21.

CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia.

Palmi C, Savino AM, Silvestri D, Bronzini I, Cario G, Paganin M, Buldini B, Galbiati M, Muckenthaler MU, Bugarin C, Della Mina P, Nagel S, Barisone E, Casale F, Locatelli F, Lo Nigro L, Micalizzi C, Parasole R, Pession A, Putti MC, Santoro N, Testi AM, Ziino O, Kulozik AE, Zimmermann M, Schrappe M, Villa A, Gaipa G, Basso G, Biondi A, Valsecchi MG, Stanulla M, Conter V, Te Kronnie G, Cazzaniga G.

Oncotarget. 2016 Sep 13;7(37):59260-59272. doi: 10.18632/oncotarget.10610.

22.

Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.

Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, Locatelli F, Cazzaniga G, Niggli F, Aricò M, Bartram CR, Attarbaschi A, Silvestri D, Beier R, Basso G, Ratei R, Kulozik AE, Lo Nigro L, Kremens B, Greiner J, Parasole R, Harbott J, Caruso R, von Stackelberg A, Barisone E, Rössig C, Conter V, Schrappe M.

Blood. 2016 Apr 28;127(17):2101-12. doi: 10.1182/blood-2015-09-670729. Epub 2016 Feb 17.

23.

Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.

Conter V, Valsecchi MG, Buldini B, Parasole R, Locatelli F, Colombini A, Rizzari C, Putti MC, Barisone E, Lo Nigro L, Santoro N, Ziino O, Pession A, Testi AM, Micalizzi C, Casale F, Pierani P, Cesaro S, Cellini M, Silvestri D, Cazzaniga G, Biondi A, Basso G.

Lancet Haematol. 2016 Feb;3(2):e80-6. doi: 10.1016/S2352-3026(15)00254-9. Epub 2016 Jan 26.

PMID:
26853647
24.

Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.

Franca R, Rebora P, Bertorello N, Fagioli F, Conter V, Biondi A, Colombini A, Micalizzi C, Zecca M, Parasole R, Petruzziello F, Basso G, Putti MC, Locatelli F, d'Adamo P, Valsecchi MG, Decorti G, Rabusin M.

Pharmacogenomics J. 2017 Jan;17(1):4-10. doi: 10.1038/tpj.2015.83. Epub 2015 Dec 8.

PMID:
26644204
25.

Risk-adapted Treatment for Severe B-Lineage Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation in Children.

Giraldi E, Provenzi M, Conter V, Colledan M, Bolognini S, Foglia C, Sebastiani R, Fiocchi R, Gianatti A, DʼAntiga L, Rambaldi A.

Transplantation. 2016 Feb;100(2):437-45. doi: 10.1097/TP.0000000000000845.

PMID:
26270449
26.

Infectious complications in children with acute lymphoblastic leukemia treated in low-middle-income countries.

Caniza MA, Odio C, Mukkada S, Gonzalez M, Ceppi F, Chaisavaneeyakorn S, Apiwattanakul N, Howard SC, Conter V, Bonilla M.

Expert Rev Hematol. 2015 Oct;8(5):627-45. doi: 10.1586/17474086.2015.1071186. Epub 2015 Jul 27. Review.

PMID:
26211675
27.

Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.

Boer JM, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, de Groot-Kruseman HA, Kuiper RP, Hoogerbrugge P, Horstmann M, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, do Socorro Pombo-de-Oliveira M, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn N, Sutton R, Schwab CJ, Enshaei A, Vora A, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmermann M, Moorman AV, Pieters R, den Boer ML.

Leukemia. 2016 Jan;30(1):32-8. doi: 10.1038/leu.2015.199. Epub 2015 Jul 23.

PMID:
26202931
28.

Supportive medical care for children with acute lymphoblastic leukemia in low- and middle-income countries.

Ceppi F, Antillon F, Pacheco C, Sullivan CE, Lam CG, Howard SC, Conter V.

Expert Rev Hematol. 2015 Oct;8(5):613-26. doi: 10.1586/17474086.2015.1049594. Epub 2015 May 26. Review.

PMID:
26013005
29.

Long-term results of the AIEOP LNH-97 protocol for childhood lymphoblastic lymphoma.

Pillon M, Aricò M, Mussolin L, Carraro E, Conter V, Sala A, Buffardi S, Garaventa A, D'Angelo P, Lo Nigro L, Santoro N, Piglione M, Lombardi A, Porta F, Cesaro S, Moleti ML, Casale F, Mura R, d'Amore ES, Basso G, Rosolen A.

Pediatr Blood Cancer. 2015 Aug;62(8):1388-94. doi: 10.1002/pbc.25469. Epub 2015 Mar 8.

PMID:
25755200
30.

Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention.

Ceppi F, Cazzaniga G, Colombini A, Biondi A, Conter V.

Expert Rev Hematol. 2015 Feb;8(1):57-70. doi: 10.1586/17474086.2015.978281. Epub 2014 Nov 4. Review.

PMID:
25367188
31.

Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group.

D'Angiò M, Valsecchi MG, Testi AM, Conter V, Nunes V, Parasole R, Colombini A, Santoro N, Varotto S, Caniglia M, Silvestri D, Consarino C, Levati L, Magrin E, Locatelli F, Basso G, Foà R, Biondi A, Cazzaniga G.

Haematologica. 2015 Jan;100(1):e10-3. doi: 10.3324/haematol.2014.112151. Epub 2014 Oct 10. No abstract available.

32.

Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia.

Paganin M, Fabbri G, Conter V, Barisone E, Polato K, Cazzaniga G, Giraldi E, Fagioli F, Aricò M, Valsecchi MG, Basso G.

J Clin Oncol. 2014 Nov 1;32(31):3553-8. doi: 10.1200/JCO.2014.56.0698. Epub 2014 Oct 6.

PMID:
25287825
33.

Low PKCα expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome.

Milani G, Rebora P, Accordi B, Galla L, Bresolin S, Cazzaniga G, Buldini B, Mura R, Ladogana S, Giraldi E, Conter V, Te Kronnie G, Valsecchi MG, Basso G.

Oncotarget. 2014 Jul 30;5(14):5234-45.

34.

Is multifocality a prognostic factor in childhood hepatoblastoma?

Saettini F, Conter V, Provenzi M, Rota M, Giraldi E, Foglia C, Cavalleri L, D'Antiga L.

Pediatr Blood Cancer. 2014 Sep;61(9):1593-7. doi: 10.1002/pbc.25077. Epub 2014 Apr 23.

PMID:
24757164
35.

Tobacco smoke and risk of childhood acute lymphoblastic leukemia: findings from the SETIL case-control study.

Farioli A, Legittimo P, Mattioli S, Miligi L, Benvenuti A, Ranucci A, Salvan A, Rondelli R, Conter V, Magnani C.

Cancer Causes Control. 2014 Jun;25(6):683-92. doi: 10.1007/s10552-014-0371-9. Epub 2014 Apr 4.

PMID:
24699944
36.

Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?

Balduzzi A, Di Maio L, Silvestri D, Songia S, Bonanomi S, Rovelli A, Conter V, Biondi A, Cazzaniga G, Valsecchi MG.

Br J Haematol. 2014 Feb;164(3):396-408. doi: 10.1111/bjh.12639.

PMID:
24422724
37.

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study.

Conter V, Valsecchi MG, Parasole R, Putti MC, Locatelli F, Barisone E, Lo Nigro L, Santoro N, Aricò M, Ziino O, Pession A, Testi AM, Micalizzi C, Casale F, Zecca M, Casazza G, Tamaro P, La Barba G, Notarangelo LD, Silvestri D, Colombini A, Rizzari C, Biondi A, Masera G, Basso G.

Blood. 2014 Mar 6;123(10):1470-8. doi: 10.1182/blood-2013-10-532598. Epub 2014 Jan 10.

38.

Childhood acute lymphoblastic leukemia in Nicaragua: long-term results in the context of an international cooperative program.

Pacheco C, Lucchini G, Valsecchi MG, Malta A, Conter V, Flores A, Biondi A, Tognoni G, Arguello M, Cavalli F, Silvestri D, Lacayo FB, Masera G.

Pediatr Blood Cancer. 2014 May;61(5):827-32. doi: 10.1002/pbc.24871. Epub 2013 Dec 27.

PMID:
24376241
39.

Asociación de Hemato-Oncología Pediátrica de Centro América (AHOPCA): a model for sustainable development in pediatric oncology.

Barr RD, Antillón Klussmann F, Baez F, Bonilla M, Moreno B, Navarrete M, Nieves R, Peña A, Conter V, De Alarcón P, Howard SC, Ribeiro RC, Rodriguez-Galindo C, Valsecchi MG, Biondi A, Velez G, Tognoni G, Cavalli F, Masera G.

Pediatr Blood Cancer. 2014 Feb;61(2):345-54. doi: 10.1002/pbc.24802. Epub 2013 Oct 18. Review.

PMID:
24376230
40.

Treatment of childhood acute lymphoblastic leukemia in central America: a lower-middle income countries experience.

Navarrete M, Rossi E, Brivio E, Carrillo JM, Bonilla M, Vasquez R, Peña A, Fu L, Martinez R, Espinoza CM, Lacayo LF, Rodriguez H, Batista R, Barr R, Howard SC, Ribeiro RC, Masera G, Biondi A, Conter V, Valsecchi MG.

Pediatr Blood Cancer. 2014 May;61(5):803-9. doi: 10.1002/pbc.24911. Epub 2013 Dec 24.

PMID:
24376115
41.
42.

Is there a role for high dose chemotherapy and blood stem cell rescue in childhood hepatoblastoma presenting with lung metastases? A case report and literature review.

Provenzi M, Saettini F, Conter V, Giraldi E, Foglia C, Cavalleri L, Colledan M, D'Antiga L, Perilongo G, Da Dalt L.

Ital J Pediatr. 2013 Oct 22;39:65. doi: 10.1186/1824-7288-39-65. Review.

43.

Is there a role for FDG-PET for the assessment of treatment efficacy in Wilms' tumor? A case report and literature review.

Provenzi M, Saettini F, Conter V, Chinaglia D, Vai P, Bruno A, Cavalleri L, Foglia C, Giraldi E, Collini P, Spreafico F.

Pediatr Hematol Oncol. 2013 Oct;30(7):633-9. doi: 10.3109/08880018.2013.832446. Review.

PMID:
24050763
44.

Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia.

La Starza R, Lettieri A, Pierini V, Nofrini V, Gorello P, Songia S, Crescenzi B, Te Kronnie G, Giordan M, Leszl A, Valsecchi MG, Aversa F, Basso G, Biondi A, Conter V, Cazzaniga G, Mecucci C.

Leuk Res. 2013 Aug;37(8):928-35. doi: 10.1016/j.leukres.2013.04.005. Epub 2013 Jun 2.

PMID:
23735857
45.

Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts.

Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, Valsecchi MG, Elia L, Testi AM, Mancini F, Conter V, te Kronnie G, Ferrara F, Di Raimondo F, Tedeschi A, Fioritoni G, Fabbiano F, Meloni G, Specchia G, Pizzolo G, Mandelli F, Guarini A, Basso G, Biondi A, Foà R.

Haematologica. 2013 Nov;98(11):1702-10. doi: 10.3324/haematol.2012.080432. Epub 2013 May 28.

46.

The principle and practice of reinduction therapy (in ALL): repetita iuvant!

Masera G, Conter V, Gaynon PS.

Klin Padiatr. 2013 May;225 Suppl 1:S57-61. doi: 10.1055/s-0033-1337965. Epub 2013 May 22. No abstract available.

PMID:
23700058
47.

Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia.

Lo Nigro L, Mirabile E, Tumino M, Caserta C, Cazzaniga G, Rizzari C, Silvestri D, Buldini B, Barisone E, Casale F, Luciani M, Locatelli F, Messina C, Micalizzi C, Pession A, Parasole R, Santoro N, Masera G, Basso G, Aricò M, Valsecchi M, Biondi A, Conter V; AIEOP—Scientific Committee of ALL.

Leukemia. 2013 Dec;27(12):2419-21. doi: 10.1038/leu.2013.149. Epub 2013 May 14. No abstract available.

PMID:
23670296
48.

Screening for coagulopathy and identification of children with acute lymphoblastic leukemia at a higher risk of symptomatic venous thrombosis: an AIEOP experience.

Santoro N, Colombini A, Silvestri D, Grassi M, Giordano P, Parasole R, Barisone E, Caruso R, Conter V, Valsecchi MG, Masera G, Rizzari C.

J Pediatr Hematol Oncol. 2013 Jul;35(5):348-55. doi: 10.1097/MPH.0b013e31828dc614.

PMID:
23619106
49.

What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?

Palmi C, Valsecchi MG, Longinotti G, Silvestri D, Carrino V, Conter V, Basso G, Biondi A, Kronnie GT, Cazzaniga G.

Haematologica. 2013 Aug;98(8):1226-31. doi: 10.3324/haematol.2012.075432. Epub 2013 Apr 12.

50.

Optimizing asparaginase therapy for acute lymphoblastic leukemia.

Rizzari C, Conter V, Starý J, Colombini A, Moericke A, Schrappe M.

Curr Opin Oncol. 2013 Mar;25 Suppl 1:S1-9. doi: 10.1097/CCO.0b013e32835d7d85. Review.

PMID:
23380829

Supplemental Content

Loading ...
Support Center